The Globe and Mail

Multifocal Motor Neuropathy Pipeline Drugs Report 2025: An Analytical Outlook Covering Emerging Drugs, Strategic Pharma Partnerships, Clinical Advancements, and Evolving Market ...

DelveInsight’s, “Multifocal Motor Neuropathy Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Multifocal Motor Neuropathy pipeline landscape.
Mena FN

Multifocal Motor Neuropathy Pipeline Insights 2025: Emerging Therapies And Breakthrough Clinical Developments Signal New Era For Rare Neurological Disorder Treatment Delveinsight

"Multifocal Motor Neuropathy Pipeline Insight"DelveInsight's analysis reveals several companies advancing innovative therapies in the multifocal motor neuropathy clinical pipeline, with groundbreaking ...
Medscape

Update on Immune-Mediated Neuropathies

Kieseier and colleagues present a review of the literature on immune-mediated neuropathies, emphasizing the immunopathologic mechanisms underlying these neuropathies. Immune-mediated neuropathies have ...
Nasdaq

argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...